Anlon Healthcare reported a stellar performance for Q2 FY27, with revenue surging 102% YoY to Rs 105.61 crore and net profit rising 84% to Rs 17.18 crore. The company is aggressively expanding its capacity in Rajkot and diversifying into CDMO and medical devices. With revenue targets set at Rs 380-400 crore for FY27, management is also planning a Rs 250 crore fundraise to fuel future growth.
Anlon Healthcare Reports Strong Financial Growth for H1 FY27
Revenue grew 102.3% YoY to Rs 105.61 crore in Q2, while PAT reached Rs 17.18 crore.
Reader Takeaway: Robust top-line expansion and entry into high-margin segments drive growth, though long working capital cycles require monitoring.
What just happened
Anlon Healthcare delivered a strong financial performance for the first half of FY27. For the quarter ended Q2 FY27, the company saw its revenue climb to Rs 105.61 crore from Rs 52.20 crore in the same period last year. Net profit also saw a significant rise, coming in at Rs 17.18 crore compared to Rs 9.32 crore in Q2 FY26. EBITDA margins showed sequential improvement, recovering to 23.9% in Q2 compared to 17.8% in Q1.
Why this matters
The jump in financials indicates that the company is successfully executing its scaling strategy. Management has maintained a strong forward-looking outlook, targeting revenue between Rs 380-400 crore for FY27 and scaling up to Rs 650-700 crore for FY28. This growth is being supported by price revisions and improved operating leverage across its existing manufacturing units.
Strategic Developments
Anlon is moving beyond its core business through strategic expansion. The company’s greenfield expansion in Rajkot is expected to add 1,200 MTPA capacity by Q1 FY28. Additionally, the company has incorporated two new subsidiaries: Anlon Biologics (peptides and biosimilars) and Anlon Medico (surgical implants). Commercial revenue from the medical device business is expected to initiate by Q4 FY27.
Risks to watch
Investors should keep an eye on the company's working capital cycle, which remains elevated at 170 to 180 days. Furthermore, the company’s ambitious expansion and CDMO timelines are subject to statutory and regulatory approvals. The long gestation period for CDMO projects—typically 3-4 years—also remains a key factor in long-term revenue predictability.
What to track next
The company has finalized plans to raise up to Rs 250 crore to support its capital expenditure. The structure and timing of this fundraising, alongside the successful commissioning of the Rajkot facility by Q1 FY28, will be critical developments for shareholders to monitor in the coming quarters.